levodopa has been researched along with alanine in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.84) | 18.7374 |
| 1990's | 2 (3.23) | 18.2507 |
| 2000's | 13 (20.97) | 29.6817 |
| 2010's | 20 (32.26) | 24.3611 |
| 2020's | 24 (38.71) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, SH; Chairoungdua, A; Endou, H; Kanai, Y; Kim, DK; Matsuo, H | 1 |
| Chez, RA; Epstein, M; Mintz, DH; Oakes, GK | 1 |
| Garcia-Sancho, FJ; Herreros, B | 1 |
| Bertoldi, M; Castellani, S; Dominici, P; Moore, PS; Voltattorni, CB | 1 |
| Bolliger, C; de Toledo, FG; Dousa, TP; Thompson, MA; Tyce, GM | 1 |
| Ali, S | 1 |
| IMAIZUMI, R; KANIIKE, K; NAMBA, J; YOSHIDA, H | 1 |
| Crisma, M; Formaggio, F; Mazaleyrat, JP; Oancea, S; Peggion, C; Toniolo, C; Wakselman, M; Wright, K | 1 |
| Bedell, JA; Bräutigam, C; Chang, YT; Hoffmann, GF; Hyland, K; Knust, A; Marsh, JL; McPherson, JD; Sharma, R | 1 |
| Chillarón, J; Fernández, E; Palacín, M; Torrents, D; Zorzano, A | 1 |
| Bryla, J; Chodnicka, K; Doroszewska, R; Drozak, J; Winiarska, K | 1 |
| Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P | 1 |
| Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L | 1 |
| Atluri, H; Mitra, AK; Talluri, RS | 1 |
| Chen, JJ; Fernandez, HH | 1 |
| Artuch, R; Briones, P; Carrilho, I; Duarte, S; Garcia-Cazorla, A; Garesse, R; Montoya, J; Nascimento, A; Ormazabal, A; Pineda, M; Sala-Castellvi, P; Serrano, M | 1 |
| Wang, Q; Ye, R; Zhou, X | 1 |
| Bertoldi, M; Voltattorni, CB | 1 |
| Bertoldi, M; Blankenstein, O; Hoefig, CS; Hoffmann, GF; Klein, J; Köhrle, J; Opladen, T; Piehl, S; Renko, K; Scanlan, TS; Schweizer, U | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M | 1 |
| Anand, R; Bhatt, M; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA | 1 |
| Dahiya, N; Kakkar, AK | 1 |
| Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M | 1 |
| Bonizzoni, E; Cattaneo, C; Sardina, M | 1 |
| Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH | 1 |
| Blair, HA; Dhillon, S | 1 |
| deSouza, RM; Schapira, A | 1 |
| Müller, T | 2 |
| Gago, MF; Magalhães, R; Marques, P; Moreira, PS; Salgado, AJ; Sousa, N; Teixeira, FG | 1 |
| Borellini, L; Comi, C; Di Fonzo, A; Lacerenza, M; Lazzeri, G; Mancini, F; Silani, V | 1 |
| Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Bonizzoni, E; Cattaneo, C; Jost, WH | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
| Parambi, DGT | 1 |
| Abdelalem Aziz Ahmed, M | 1 |
| Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A | 2 |
| Ishida, T; Koebisu, M | 1 |
| El-Kosasy, AM; Hussein, LA; Mohamed, NM; Salama, NN | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G | 1 |
| Carrara, F; Corrù, F; Elia, AE; Fittipaldo, VA; Giossi, R; Lo Re, F; Mazzari, M; Pani, A; Scaglione, F; Schicchi, A; Senatore, M; Tramacere, I | 1 |
| De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A | 1 |
| Abbruzzese, G; Barone, P; Lopiano, L; Stocchi, F | 1 |
| Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y | 1 |
| Larson, D; Simuni, T | 1 |
| Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Hattori, N; Ishida, T; Kamei, T; Koebis, M; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Alonso-Cánovas, A; Baena-Álvarez, B; Beltrán-Corbellini, Á; Chico-García, JL; López-Sendón, JL; Martínez-Castrillo, JC; Pagonabarraga, J; Pareés, I; Parra-Díaz, P; Pérez-Torre, P; Rodríguez-Jorge, F | 1 |
| Huot, P; Lachance, L | 1 |
| Hattori, N; Ishida, T; Kamei, T; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Hirano, M; Isono, C; Nagai, Y; Samukawa, M | 1 |
| Bai, Y; Ding, H; Ding, L; Li, F; Liang, S; Zhang, L; Zhang, X | 1 |
18 review(s) available for levodopa and alanine
| Article | Year |
|---|---|
Safinamide: from molecular targets to a new anti-Parkinson drug.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Brain Ischemia; Disease Models, Animal; Gerbillinae; Humans; Kainic Acid; Levodopa; Mice; MPTP Poisoning; Neurons; Rats; Veratridine | 2006 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2014 |
Management of Parkinson׳s disease: Current and future pharmacotherapy.
Topics: Adenosine A2 Receptor Antagonists; Alanine; Animals; Benzylamines; Drug Therapy; Humans; Levodopa; Parkinson Disease | 2015 |
Safinamide: A Review in Parkinson's Disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2017 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Safinamide: a new hope for Parkinson's disease?
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2018 |
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2019 |
Safinamide in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Young Adult | 2020 |
Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2021 |
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Treatment Outcome | 2021 |
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
11 trial(s) available for levodopa and alanine
| Article | Year |
|---|---|
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Topics: Adult; Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pilot Projects; Treatment Outcome | 2006 |
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index | 2014 |
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index | 2020 |
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease | 2021 |
Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
33 other study(ies) available for levodopa and alanine
| Article | Year |
|---|---|
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
Topics: Amino Acid Sequence; Amino Acid Transport Systems; Amino Acid Transport Systems, Neutral; Animals; Anion Transport Proteins; Bacterial Proteins; Carrier Proteins; Cloning, Molecular; Escherichia coli Proteins; Female; Intestine, Small; Kinetics; Levodopa; Mice; Molecular Sequence Data; Oocytes; Phenylalanine; Rats; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity; Tryptophan; Tyrosine; Xenopus laevis | 2001 |
Fetal pancreatic glucagon responses in glucose-intolerant nonhuman primate pregnancy.
Topics: Alanine; Animals; Blood Glucose; Diabetes Mellitus; Female; Glucagon; Haplorhini; Levodopa; Macaca mulatta; Pancreas; Pregnancy; Pregnancy in Diabetics; Streptozocin | 1977 |
Characterization of transport systems for the transfer of 3,4-L-dihydroxyphenylalanine into slices of rat cerebral cortex.
Topics: Alanine; Amino Acids; Animals; Biological Transport; Cerebral Cortex; Histidine; Kinetics; Leucine; Levodopa; Male; Potassium; Rats; Sodium | 1975 |
Mutation of cysteine 111 in Dopa decarboxylase leads to active site perturbation.
Topics: 5-Hydroxytryptophan; Alanine; Animals; Base Sequence; Binding Sites; Circular Dichroism; Cysteine; Dopa Decarboxylase; Hydrogen-Ion Concentration; Kidney; Kinetics; Levodopa; Mutagenesis, Site-Directed; Pyridoxal Phosphate; Serine; Spectrometry, Fluorescence; Spectrophotometry; Structure-Activity Relationship; Swine | 1997 |
gamma-L-glutamyl-L-DOPA inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate.
Topics: Alanine; Animals; Biological Transport; Calcium; Carrier Proteins; Cyclic AMP; Cyclic GMP; Dihydroxyphenylalanine; Dopamine; gamma-Glutamyltransferase; Kidney Tubules, Proximal; Levodopa; Male; Microvilli; Norepinephrine; Parathyroidectomy; Phosphates; Potassium; Proline; Rats; Sodium; Sodium-Phosphate Cotransporter Proteins; Symporters; Tritium | 1999 |
Microbiological transformation of L-tyrosine to 3,4-dihydroxyphenyl L-alanine (L-dopa) by a mutant strain of Aspergillus oryzae UV-7.
Topics: Alanine; Aspergillus oryzae; Biotransformation; Fermentation; Levodopa; Mutation; Temperature; Time Factors; Tyrosine | 2002 |
STUDIES ON ACTIVE TRANSPORT OF L-DOPA (DIHYDROXYPHENYLALANINE) INTO BRAIN SLICES.
Topics: Acetates; Alanine; Aniline Compounds; Animals; Biological Transport, Active; Calcium; Calcium, Dietary; Cerebral Cortex; Dihydroxyphenylalanine; Glutamates; Guinea Pigs; Ions; Levodopa; Magnesium; Metabolism; Phenols; Phenylalanine; Research; Sodium; Tyrosine | 1963 |
New tools for the control of peptide conformation and supramolecular chemistry: crown-carrier, C(alpha)-methyl L-DOPA amino acids.
Topics: Alanine; Amino Acid Sequence; Aminoisobutyric Acids; Circular Dichroism; Levodopa; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Protein Structure, Secondary; Spectroscopy, Fourier Transform Infrared | 2003 |
Levodopa-responsive aromatic L-amino acid decarboxylase deficiency.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Binding Sites; Carbidopa; Chromatography, High Pressure Liquid; Developmental Disabilities; DNA Mutational Analysis; Drug Combinations; Electrochemistry; Family Health; Female; Glycine; Humans; Levodopa; Male; Models, Structural; Point Mutation; Protein Binding; Protein Conformation | 2004 |
Identification and functional characterization of a novel low affinity aromatic-preferring amino acid transporter (arpAT). One of the few proteins silenced during primate evolution.
Topics: Alanine; Amino Acid Sequence; Amino Acid Transport Systems; Amino Acid Transport Systems, Neutral; Amino Acids; Amino Acids, Aromatic; Animals; Arginine; Biological Transport; Blotting, Northern; Blotting, Western; Cell Lineage; Chickens; Cloning, Molecular; Cysteine; Dimerization; DNA, Complementary; Dogs; Dose-Response Relationship, Drug; Evolution, Molecular; Gene Library; Gene Silencing; Glutamine; Glycine; HeLa Cells; Humans; In Situ Hybridization; Inhibitory Concentration 50; Intestine, Small; Kidney; Kinetics; Levodopa; Mice; Molecular Sequence Data; Open Reading Frames; Pan troglodytes; Phylogeny; Proline; Protein Binding; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Sodium; Transfection | 2005 |
Contribution of L-3,4-dihydroxyphenylalanine metabolism to the inhibition of gluconeogenesis in rabbit kidney-cortex tubules.
Topics: Alanine; Animals; Aspartic Acid; Caprylates; Depression, Chemical; Dihydroxyacetone; Dopamine; Gluconeogenesis; Glutathione; Glutathione Disulfide; Glycerol; Hydrogen Peroxide; In Vitro Techniques; Kidney Tubules; Levodopa; Male; Phosphoenolpyruvate Carboxykinase (GTP); Pyruvic Acid; Rabbits; Selegiline; Tyramine | 2005 |
Functional activity of a large neutral amino acid transporter (LAT) in rabbit retina: a study involving the in vivo retinal uptake and vitreal pharmacokinetics of L-phenyl alanine.
Topics: Alanine; Amino Acid Transport System L; Amino Acids; Amino Acids, Cyclic; Aminoisobutyric Acids; Animals; Area Under Curve; Binding, Competitive; Gene Expression; Large Neutral Amino Acid-Transporter 1; Levodopa; Male; Membrane Transport Modulators; Methionine; Phenylalanine; Protein Isoforms; Rabbits; Retina | 2008 |
Mitochondrial diseases mimicking neurotransmitter defects.
Topics: Alanine; Brain; Child, Preschool; Consanguinity; Diagnosis, Differential; Dopamine Agents; Dystonia; Electron Transport Complex I; Electron Transport Complex II; Electron Transport Complex III; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Infant; Infant, Newborn; Lactic Acid; Levodopa; Male; Mitochondrial Diseases; Neurotransmitter Agents; Pterins; Radiography; Treatment Outcome | 2008 |
Lincomycin, rational selection of high producing strain and improved fermentation by amino acids supplementation.
Topics: Alanine; Amino Acids; Anti-Bacterial Agents; Biomedical Engineering; Bioreactors; Fermentation; Levodopa; Lincomycin; Mutation; Proline; Pyruvate Kinase; Streptomyces; Tyrosine | 2009 |
Multiple roles of the active site lysine of Dopa decarboxylase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alanine; Amino Acid Substitution; Ammonia; Animals; Binding Sites; Catalysis; Deamination; Decarboxylation; Dopa Decarboxylase; Dopamine; Hydrogen Bonding; Hydrolysis; Kidney; Kinetics; Levodopa; Lysine; Models, Chemical; Molecular Structure; Oxidation-Reduction; Protein Binding; Protein Conformation; Pyridoxal Phosphate; Structure-Activity Relationship; Swine | 2009 |
Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis?
Topics: Alanine; Aromatic-L-Amino-Acid Decarboxylases; Chromatography, Liquid; Decarboxylation; Dopamine; Humans; Levodopa; Signal Transduction; Solutions; Substrate Specificity; Tandem Mass Spectrometry; Thyroid Gland; Thyroid Hormones; Thyronines | 2012 |
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome | 2013 |
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2018 |
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |
[Safinamide Mesilate (Equfina
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Mesylates; Rats; Tablets | 2020 |
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2020 |
New and validated RP-HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma.
Topics: Alanine; Benzylamines; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Levodopa; Limit of Detection; Linear Models; Ondansetron; Reproducibility of Results; Tablets | 2020 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Executive Function; Humans; Levodopa; Parkinson Disease | 2021 |
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
Topics: Alanine; Antiparkinson Agents; Behavioral Symptoms; Benzylamines; Cognition; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2022 |
Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease | 2022 |
Pemphigoid-like Skin Lesions Following Introduction of Safinamide.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Pemphigoid, Bullous | 2023 |
The effects of safinamide on dysphagia in Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Deglutition Disorders; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies | 2023 |
Flexible Strain-Sensitive Sensors Assembled from Mussel-inspired Hydrogel with Tunable Mechanical Properties and Wide Temperature Tolerance in Multiple Application Scenarios.
Topics: Adhesiveness; Alanine; Electric Conductivity; Humans; Hydrogels; Levodopa; Temperature | 2023 |